Thermo Fisher Scientific announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco.
The new center provides pharmaceutical and biotechnology makers with hands-on access to cryo-EM technologies designed to accelerate structural insights and the development of therapies.
The CDDC provides direct access to advanced cryo-EM innovation and scientific expertise while lowering the barriers to adoption. The use of cryo-EM not only expands the range of therapeutic targets and advanced therapies for structure-based methods but also can help pharmaceutical companies get drugs to clinics faster.
The opening of the center in the Oyster Point area of South San Francisco builds on the success of the UK Pharmaceutical Cryo-EM Consortium, established in Cambridge, United Kingdom, in 2016. Now celebrating its 10-year anniversary, the consortium represents a collaboration between Thermo Fisher Scientific and five pharmaceutical companies. Modeled after this partnership framework, the new U.S.-based CDDC will include founding customer members to extend this collaborative approach to the North American market.
